New Method Detects Performance-Enhancing Peptide TB-500 in Racehorses
Background
TB-500 is a synthetic peptide derived from thymosin beta-4, a naturally occurring protein known for its roles in cell migration, wound healing, and tissue repair. Due to its regenerative properties, TB-500 has been illicitly used as a performance-enhancing drug in competitive sports, particularly in equine racing, to accelerate recovery from injuries and improve athletic performance. The lack of a robust and sensitive analytical method for its detection in biological samples posed a significant challenge for doping control authorities.
Results
The developed LC-MS method demonstrated excellent sensitivity and specificity for TB-500 in both matrices. The limit of detection (LOD) was established at 0.2 ng/mL in urine and 0.5 ng/mL in plasma, with a limit of quantification (LOQ) of 0.5 ng/mL and 1.0 ng/mL, respectively. In the administered horses, TB-500 was consistently detected in urine samples for up to 96 hours post-administration and in plasma for approximately 48 hours. The method showed high recovery rates, averaging 85-95% across various concentrations, and negligible matrix effects. The developed LC-MS method achieved a remarkable limit of detection of 0.2 ng/mL in equine urine, allowing for the reliable detection of TB-500 for up to 96 hours after a single dose, significantly enhancing doping control capabilities.
Why It Matters
This study provides a crucial analytical tool for anti-doping laboratories worldwide, enabling the effective detection of TB-500 in equine sports. The high sensitivity and specificity of the LC-MS method will significantly deter the illicit use of this peptide, promoting fair competition and safeguarding animal welfare. The successful validation of this method paves the way for its routine implementation in doping control programs, potentially leading to a cleaner sport environment. Future steps include inter-laboratory validation and application in real-world screening scenarios.